Core Insights - Ascentage Pharma announced new clinical data for its drug candidates, lisaftoclax and alrizomadlin, which will be presented at the 2025 ASCO Annual Meeting, indicating their potential in treating various cancers [1][2] Group 1: Lisaftoclax - Lisaftoclax is a Bcl-2 inhibitor being evaluated in a Phase 1b/2 study in combination with azacitidine for treatment-naïve or prior venetoclax-exposed myeloid malignancies [2][5] - The study enrolled nearly 100 patients, showing that the combination was well tolerated with preliminary efficacy; the overall response rate (ORR) for treatment-naïve myelodysplastic syndromes (MDS) was 64% [6][8] - In patients with venetoclax-refractory acute myeloid leukemia (AML), the ORR was 17%, while for high-risk MDS, it was 50% [6][8] Group 2: Alrizomadlin - Alrizomadlin is an MDM2-p53 inhibitor showing initial clinical activity in advanced adenoid cystic carcinoma (ACC) and other solid tumors [9][10] - The monotherapy arm demonstrated an ORR of 22.2% in ACC patients, with a disease control rate (DCR) of 100% in MPNST patients [12] - In the combination arm with toripalimab, the ORR was 20% in biliary-tract cancer patients, and 16.7% in liposarcoma patients, with prolonged progression-free survival observed in some MPNST patients [13]

在4月29日观点指数研究院发布的《运营承压与融资纾困 | 2025一季度不动产资本金融报告》中，我们 发现，一季度中概股、港股、A股不动产行业IPO募资数量和规模占比没有太大变化。联掌门户、三易 科技等案例，印证社区流量价值与物业管理数字化已经成为资本新焦点，智能立体车库等细分赛道依托 政策红利快速崛起。 观点指数 2025年一季度，中国不动产资本市场在政策调整、融资约束与行业出清的多重压力下，呈现 出深度分化与结构性变革的特征。资本市场端，IPO市场呈现"小额高频"趋势，中概股募资规模缩水但 估值逻辑转向场景流量与技术驱动，港股打破传统淡季规律实现量价齐升，A股融资规模则延续收缩， 但行业分布向高附加值领域集中。联掌门户、三易科技等案例，印证社区流量价值与物业管理数字化已 经成为资本新焦点，智能立体车库等细分赛道依托政策红利快速崛起。 一季度IPO整体变化趋势 中概股"小额高频"发行模式：中概股IPO数量从13家增长到22家，募资总额从16.78亿美元下降到2.84亿 美元。去除极端数据后的均值可以更准确地反映大部分IPO的平均情况，2024年一季度亚玛芬体育募资 15.71亿美元，扣除亚玛芬体育后2024 ...

Investment Rating - The report maintains an investment rating of "Outperform" with a rating of A [4] Core Insights - The innovative drug sector has seen a significant increase in institutional preference, with the total heavy positions in Biotech innovative drugs reaching 57.62 billion, a quarter-on-quarter increase of 62% [9][19] - The heavy positions in Biotech innovative drugs accounted for 1.90% of the total market heavy positions, up by 0.79 percentage points, and 19.43% of the heavy positions in the pharmaceutical industry, up by 6.36 percentage points [9][21] - The report highlights that the preference for innovative drugs is driven by continuous revenue and profit realization from domestic sales and overseas licensing, along with anticipated catalysts from upcoming academic conferences in Q2 [19][21] Weekly New Drug Market Review - From April 28 to May 2, 2025, the top five companies in the new drug sector by stock price increase were: Aidi Pharmaceutical (19.49%), Kelun-Botai Biological (17.02%), Lepu Biopharma (16.09%), Connora (13.61%), and Canaan Pharma (13.60%) [15][17] - The top five companies by stock price decrease were: Kangfang Biopharma (-11.22%), Yiming Oncology (-10.03%), Dongyao Pharmaceutical (-6.90%), Maibo Pharmaceutical (-6.52%), and Ascentage Pharma (-5.63%) [15][17] New Drug Application Approvals and Acceptances - No new drug or new indication applications were approved this week; however, six new drug or new indication applications were accepted, including Biocodex's Sitalopram Capsules and BeiGene's Sotoclar Tablets [33][34] New Drug Clinical Application Approvals and Acceptances - This week, 33 new drug clinical applications were approved, and 36 new drug clinical applications were accepted [37][39]

Investment Rating - The report maintains an investment rating of "Outperform" with a rating of A [4] Core Insights - The innovative drug sector has seen a significant increase in institutional preference, with the total heavy positions in Biotech innovative drugs reaching 57.62 billion, a quarter-on-quarter increase of 62% [9][19] - The heavy positions in Biotech innovative drugs accounted for 1.90% of the total market heavy positions, up by 0.79 percentage points, and 19.43% of the heavy positions in the pharmaceutical industry, up by 6.36 percentage points [9][21] - The report highlights that the preference for innovative drugs is driven by continuous revenue and profit realization from domestic sales and overseas licensing, along with anticipated catalysts from upcoming academic conferences in Q2 [19][21] Weekly New Drug Market Review - From April 28 to May 2, 2025, the top five companies in the new drug sector by stock price increase were: Aidi Pharmaceutical (19.49%), Kelun-Botai Biopharmaceutical (17.02%), Lepu Biopharmaceutical (16.09%), Connora (13.61%), and Canaan Pharma (13.60%) [15] - The top five companies by stock price decrease were: Kangfang Biopharmaceutical (-11.22%), Yiming Oncology (-10.03%), Dongyao Pharmaceutical (-6.90%), Maibo Pharmaceutical (-6.52%), and Ascentage Pharma (-5.63%) [15] Weekly New Drug Industry Analysis - The report analyzed the latest heavy positions of all funds in the innovative drug sector as of March 31, 2025, focusing on A-share and Hong Kong Biotech companies [19] - The heavy positions in Biotech innovative drugs represented 6.11% of the total market circulation value, an increase of 0.90 percentage points [24][31] Weekly New Drug Approval & Acceptance Status - No new drug or new indication applications were approved this week; however, six new drug or new indication applications were accepted, including Biocodex's Sitalopram Capsules and BeiGene's Sotoclar Tablets [33][34] Weekly New Drug Clinical Application Approval & Acceptance Status - This week, 33 new drug clinical applications were approved, and 36 new drug clinical applications were accepted [37]

Group 1 - The core viewpoint of the article highlights the significant growth in revenue and net profit for Ascentage Pharma (AAPG), with a revenue increase of 341.77% year-on-year and a net profit increase of 56.2% [1][2] - Ascentage Pharma is a biopharmaceutical company based in China, focusing on developing innovative drugs for cancer, hepatitis B, and age-related diseases, with a strong emphasis on apoptosis pathway drug development [2] - The company has established a pipeline of nine clinical-stage first-class small molecule drugs, including inhibitors targeting key proteins in the apoptosis pathway, and is conducting over 40 clinical trials globally [2] Group 2 - Ascentage Pharma's core product, Olverembatinib (brand name: Nilotinib), has received priority review and breakthrough therapy designation from the Chinese National Medical Products Administration and has been included in the National Basic Medical Insurance Drug List [2] - The company has achieved multiple designations from the FDA, including orphan drug status and fast track designation for four investigational new drugs, demonstrating its strong regulatory engagement [2] - Ascentage Pharma has formed global collaborations with leading biotech and pharmaceutical companies and academic institutions, enhancing its research capabilities and market presence [2]

Core Insights - Ascentage Pharma presented results from five preclinical studies at the 2025 AACR Annual Meeting, showcasing its innovative drug pipeline targeting hematological malignancies [1][3][19] Group 1: Drug Candidates and Their Mechanisms - The five drug candidates presented include olverembatinib (HQP1351), lisaftoclax (APG-2575), APG-2449, APG-5918, and AS03157, each targeting different pathways in cancer treatment [2][19] - Olverembatinib combined with lisaftoclax showed strong synergistic effects in overcoming venetoclax resistance in acute myeloid leukemia (AML) models, indicating potential for new therapeutic strategies [4][7] - APG-5918, an EED inhibitor, demonstrated potent antitumor activity and synergized with enzalutamide in preclinical prostate cancer models, suggesting a promising combination therapy [10][16] - APG-2449, a FAK inhibitor, enhanced the antitumor activity of chemotherapy in small-cell lung cancer (SCLC) models, supporting its further clinical development [13][17] - AS03157, an IAP antagonist, showed high affinity for cIAP1 and XIAP, with potent antiproliferative activities in cancer cell lines, indicating its potential as a therapeutic candidate [25] Group 2: Clinical Development and Regulatory Status - Olverembatinib is already approved in China and included in the National Reimbursement Drug List, while a New Drug Application for lisaftoclax has been accepted for Priority Review by the China CDE [21][22] - Ascentage Pharma has received 16 Orphan Drug Designations from the US FDA and 1 from the EMA for its investigational drug candidates, highlighting its commitment to addressing unmet medical needs [22][19] Group 3: Company Overview and Strategic Goals - Ascentage Pharma is focused on discovering and developing therapies for hematological malignancies, with a robust pipeline of innovative drug candidates [19][20] - The company aims to strengthen its R&D capabilities and accelerate clinical development programs to meet global clinical needs [23]

Investment Rating - The report maintains an investment rating of "Outperform the Market - A" for the biopharmaceutical sector [6]. Core Insights - The ASCO 2025 conference is set to take place from May 30 to June 3, 2025, and several domestic pharmaceutical companies are expected to present new clinical data, with potential for exceeding expectations [2][14]. - A total of 13 new drugs or new indications were approved for market launch in the past week, alongside 50 new drug IND approvals and 27 IND applications accepted [3][17]. Weekly New Drug Market Review - From April 21 to April 27, 2025, the top five companies in the new drug sector by stock price increase were: - Yiming Oncology: +40.20% - Ascentage Pharma: +38.63% - Genscript Biotech: +27.13% - JACOB: +24.52% - Kedi: +24.02% - The top five companies by stock price decrease were: - Boan Biotech: -23.11% - ZhiXiang JinTai: -7.30% - Maibo Pharmaceutical: -7.07% - Aidi Pharmaceutical: -6.30% - Haizhi Pharmaceutical: -3.76% [10][11]. Weekly New Drug Industry Key Analysis - The ASCO 2025 conference will feature multiple oral presentations from domestic companies, including: - Innovent Biologics: PD-1/IL-2 dual antibody with three oral reports and Claudin18.2 ADC with one oral report. - Other companies such as Kelun Biotech, BaiLi TianHeng, and Hengrui Medicine are also expected to present various new drugs and indications [2][14][15]. Weekly New Drug Approvals & Acceptance - The report highlights the approval of 13 new drugs or new indications, including: - Canfuo Biotech's PD-1/VEGF dual-specificity tumor immunotherapy drug approved for new indications. - AstraZeneca's Dupixent for chronic spontaneous urticaria in patients aged 12 and older [4][18]. - Additionally, 50 new drug INDs were approved, and 27 IND applications were accepted [3][17]. Domestic New Drug Industry Focus - Key highlights include: - Canfuo Biotech's PD-1 monoclonal antibody approved by the FDA for metastatic nasopharyngeal carcinoma. - Canfuo Biotech's new indication for its PD-1/VEGF dual-specificity drug approved by NMPA for non-small cell lung cancer. - Novartis' BTK inhibitor approved for chronic lymphocytic leukemia [4][18]. Overseas New Drug Industry Focus - Notable developments include: - Sanofi's Dupixent for chronic spontaneous urticaria approved by the FDA. - AstraZeneca's Enhertu showing positive results in clinical trials for HER2-positive metastatic breast cancer. - Gilead Sciences' Trodelvy achieving positive results in clinical studies [5][7].

Market Overview - The US stock market experienced a pullback after a brief rally, with the Hong Kong stock market also declining by 0.74% [1] - President Trump indicated potential new tariffs on trade partners, including China, which has led to skepticism in the market regarding the actual implementation of these tariffs [1] - The White House's claims of progress in trade negotiations with allies have been denied by those countries, indicating a lack of consensus [1] Gold Market Activity - Gold prices have become active again, with Deutsche Bank attributing recent declines to a rebound in the US dollar and market overreaction to tariff news [2] - Despite the recent pullback, the outlook for gold remains positive due to ongoing uncertainties surrounding US tariffs [2] - Several gold mining companies, including Lingbao Gold and Shandong Gold, saw rebounds in their stock prices [2] Japanese Market Investment - Overseas investors have net purchased 9.64 trillion yen (approximately 675 billion) in Japanese bonds and stocks, marking the highest level since records began in 1996 [3] - A significant portion of this investment has flowed into the Japanese bond market, indicating a potential future interest in the Chinese market [3] Banking Sector Performance - A-share listed banks reported strong growth in revenue and net profit for Q1 2025, with steady credit expansion [3] - Major banks in China, including the "Big Four," have seen their stock prices reach historical highs, reflecting investor confidence [3] New Consumption Trends - Investment is shifting towards new consumption sectors such as personal care, cosmetics, and jewelry, with companies like Shangmei and Juzhong Biotech showing strong performance [4] - Shangmei's recent partnership and its leading position in the beauty market highlight the growth potential in this sector [4] Oncology Sector Developments - The upcoming ASCO 2025 conference will showcase significant clinical advancements from companies like Rongchang Biotech and Ascentage Pharma, with multiple projects selected for presentation [5][6] - Rongchang Biotech's stock surged over 17% following the announcement of its clinical progress [5] Wind Power Industry Insights - Wind power companies have reported strong Q1 results, with expectations for increased demand and improved operational efficiency in the coming years [7] - The domestic wind power installation forecast for 2025 and 2026 shows significant growth, particularly in offshore wind projects [7] Individual Company Highlights - TCL Electronics announced a new stock incentive plan aimed at boosting employee confidence and aligning with its global growth strategy [9] - The company reported a projected revenue increase of 25.7% for 2024, with significant growth in its innovative business segments, including solar energy [10]

智通财经APP获悉，港股未能延续昨日强劲走势，三大指数集体下挫，恒指失守两万二大关，恒科指盘 中一度跌超2%。截止收盘，恒生指数跌0.74%或162.86点，报21909.76点，全日成交额2047.6亿港元； 恒生国企指数跌0.73%，报8056.85点；恒生科技指数跌1.46%，报4975.89点。 华泰证券指出，对等关税扰动发生后，坚定看好港股相对收益表现，原因有三点：第一，产业上，市场 中业绩与关税敏感性较高的出口链及中游制造企业市值占比较低；第二，科技企业盈利表现或将持续支 持港股行情演绎；第三，外部扰动下，市场或对内需政策存在较大预期。 蓝筹股表现 新东方-S(09901)探底回升。截至收盘，涨1.69%，报36.05港元，成交额4.43亿港元，贡献恒指0.67点。 新东方2025财年第三财季收入同比跌2%，教育业务收入同比升21%；股东应占净利润同比上升0.1%至 8726万美元。高盛预期，若公司可在第四财季实现利润率扩张，届时投资者信心将得到改善，估值可望 提升。 2. 内房股多数上扬。截至收盘，融创中国(01918)涨5.06%，报1.66港元；富力地产(02777)涨4.81%，报 1.0 ...

Core Insights - The Chinese innovative drug market is projected to exceed 1.13 trillion yuan in 2024, with expectations to approach 2.3 trillion yuan by 2030, indicating a high growth trend in the sector [1] - The Hong Kong pharmaceutical ETF (159718) has shown a recent decline of 0.28%, but has increased by 7.16% over the past week [1] - The liquidity of the Hong Kong pharmaceutical ETF is active, with a turnover of 17.21% and a transaction volume of 50.91 million yuan [2] Group 1: Market Performance - As of April 24, 2025, notable stock performances include Xintai Medical (02291) up 13.86%, Ascentage Pharma-B (06855) up 7.36%, and Innovent Biologics (01801) up 4.18% [1] - The Medical Innovation ETF (516820) has a recent turnover of 1.7% and a transaction volume of 28.42 million yuan, with an average daily transaction of 53.10 million yuan over the past month [4] Group 2: Index and Weighting - The CSI Hong Kong Stock Connect Healthcare Index (930965) includes 50 liquid and large-cap healthcare companies, with the top ten stocks accounting for 59.76% of the index [6] - The top ten stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) account for 66.49%, indicating a concentration in leading companies [9] Group 3: Investment Outlook - The manager of Ping An Healthcare Fund, Zhou Sicong, emphasizes that the export of innovative drugs is largely unaffected by U.S. tariff policies due to factors such as high profit margins and the nature of intellectual property [2] - The innovative drug sector is expected to have a promising outlook for Chinese companies, with investors advised not to overreact to short-term policy fluctuations [2]